Free Trial
NASDAQ:OTLK

Outlook Therapeutics (OTLK) Stock Price, News & Analysis

Outlook Therapeutics logo
$5.03 -0.10 (-1.95%)
(As of 11/22/2024 ET)

About Outlook Therapeutics Stock (NASDAQ:OTLK)

Key Stats

Today's Range
$4.99
$5.24
50-Day Range
$4.94
$6.67
52-Week Range
$4.61
$12.85
Volume
330,142 shs
Average Volume
343,400 shs
Market Capitalization
$118.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.20
Consensus Rating
Buy

Company Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

OTLK MarketRank™: 

Outlook Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 849th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Outlook Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Outlook Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Outlook Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Outlook Therapeutics are expected to grow in the coming year, from ($3.84) to ($2.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Outlook Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Outlook Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Outlook Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    21.21% of the float of Outlook Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Outlook Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Outlook Therapeutics has recently increased by 8.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Outlook Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Outlook Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.21% of the float of Outlook Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Outlook Therapeutics has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Outlook Therapeutics has recently increased by 8.03%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 22 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,450.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 3.40% of the stock of Outlook Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 11.20% of the stock of Outlook Therapeutics is held by institutions.

  • Read more about Outlook Therapeutics' insider trading history.
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OTLK Stock News Headlines

917 Trades… Zero Losses?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
See More Headlines

OTLK Stock Analysis - Frequently Asked Questions

Outlook Therapeutics' stock was trading at $7.88 at the start of the year. Since then, OTLK stock has decreased by 36.2% and is now trading at $5.03.
View the best growth stocks for 2024 here
.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) released its quarterly earnings data on Wednesday, December, 22nd. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.20) by $0.60.

Outlook Therapeutics shares reverse split on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of Outlook Therapeutics include Great Point Partners LLC (5.47%), Sphera Funds Management LTD. (1.75%), Geode Capital Management LLC (1.45%) and Caligan Partners LP (1.35%). Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon, Yezan Munther Haddadin, C Russell Trenary III and Ghiath M Sukhtian.
View institutional ownership trends
.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Outlook Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
12/22/2021
Today
11/23/2024
Next Earnings (Estimated)
12/27/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.20
High Stock Price Target
$100.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+858.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-58,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.11) per share

Miscellaneous

Free Float
22,852,000
Market Cap
$118.99 million
Optionable
Optionable
Beta
0.62
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:OTLK) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners